NCT03427242Unknown2 期
A Phase II Study of Apatinib Treatment for Advanced Biliary Tract Carcinoma After Failure of the First-line Chemotherapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 55
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
This is a phase II open-label, one-arm, single-center study of apatinib for eligible patients with advanced biliary tract carcinoma after the first-line treatment failure. A total of 55 patients is planned for enrollment. The time for enrollment is from Nov 2017 to Nov 2020, the the follow-up will be ended after Nov 2021. Patients in the study would receive oral apatinib 500-750mg qd until progression of disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients age between 18 and 70 years
- •Histologically confirmed advanced biliary tract carcinoma (BTC) or metastatic BTC
- •Prior lack of response or intolerance to at least one chemotherapeutic regimens (including gemcitabine).
- •At least one measurable lesion as defined by RECIST 1.1
- •An Eastern Cooperative Oncology Group performance status of 0 to 2
- •Life expectancy ≥ 12 weeks
- •For those who received other anti-tumor treatment, the damage should have been restored, with the time interval from last dose of nitroso or mitomycin≥6 weeks and interval from last dose of other cytotoxic drugs, radiation or surgery (the wound should be healed completely) ≥4 weeks.
- •Acceptable hematologic, hepatic, and renal function within 7 days from screening： the blood ANC count≥1.5x109 /L; hemoglobin ≥ 9.0 g/dl，the blood platelet count≥80 x109 /L, total bilirubin < 1.5 x ULN, ALT and AST< 2.5 x ULN(< 5 x ULN for patients with live metastasis), serum creatinine≤1 x ULN，endogenous creatinine clearance rate >50ml/min
- •Women of reproductive age need to take effective contraceptive measures
排除标准
- •With other malignant tumor in 5 years，except for cured cervical carcinoma in situ or basal cell carcinoma.
- •Uncontrolled blood pressure on medication (140/90 mmHg); patients with > Grade 1 coronary heart disease, cardiac arrhythmias or cardiac dysfunction
- •Symptomatic brain or meningeal metastasis
- •History of uncontrolled seizures, central nervous system dysfunction or mental disorder
- •Uncontrolled pleural or peritoneal effusion
- •Undergoing dialysis
- •Severe or uncontrolled infection
- •With multiple factors that affecting oral administration
- •Abnormal coagulation function or those receiving thrombolytics or anticoagulants
- •Patients with tendency of gastrointestinal hemorrhage, including active peptic ulcer with fecal occult blood ++, hematemesis or melena within 3 months
- •Participation in other drug clinical trials within 4 weeks
- •Weight below 40kg
- •urine protein ≥2+
研究组 & 干预措施
treatment arm
Experimental
oral apatinib
干预措施: Apatinib (Drug)
结局指标
主要结局
PFS
时间窗: from the time signing of ICF until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months
progression free survival
次要结局
- OS(from the time signing of ICF until the date of death from any cause, assessed up to 48 months)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric CancerMetastasisGastric CancerNCT05095636Fudan University102
Unknown
2 期
An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and GastricEsophagus Cancer, Stage IIIEsophageal Gastric Cardia Type MetaplasiaEsophagus Cancer, Stage IVNCT03285906Tianjin Medical University Cancer Institute and Hospital30
Unknown
1 期
Study of Apatinib and MASCT in Patients With Advanced Solid TumorsAdvanced Solid TumorsExcluding T Cell LymphomaNCT02844881The First People's Hospital of Lianyungang60
Unknown
2 期
Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical ResectionCarcinoma, HepatocellularNCT03261791Shanghai Zhongshan Hospital30
招募中
2 期
Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in ChildrenRecurrent MedulloblastomaNCT04501718Beijing Sanbo Brain Hospital44